SULT2A1

Across TCGA pan-cancer cohorts, SULT2A1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SULT2A1 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher SULT2A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SULT2A1 expression acts as an unfavorable survival marker.

LAML, KIRC, and LUAD are the cancer types where SULT2A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
LUAD	OS	Median	II,III,IV	0.090	0.709	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	All	0.200	0.511	.038	6	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SULT2A1–LAML (DFS)

Open the LAML breakdown →